{"id":814028,"date":"2025-02-18T08:09:31","date_gmt":"2025-02-18T13:09:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/"},"modified":"2025-02-18T08:09:31","modified_gmt":"2025-02-18T13:09:31","slug":"windtree-therapeutics-inc-announces-reverse-stock-split","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/","title":{"rendered":"Windtree Therapeutics, Inc. Announces Reverse Stock Split"},"content":{"rendered":"
\n

WARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (\u201cWindtree\u201d or the \u201cCompany\u201d), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company\u2019s common stock. The Company\u2019s stockholders approved the reverse stock split proposal at the Company\u2019s Special Meeting of Stockholders held on February 3, 2025. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.<\/p>\n

The reverse stock split will become effective on February 20, 2025 at 5:00 p.m., Eastern Time (the \u201cEffective Time\u201d), and the Company\u2019s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (\u201cNasdaq\u201d) on February 21, 2025 at market open under the existing ticker symbol, \u201cWINT.\u201d The reverse stock split is intended to increase the price per share of the Company\u2019s common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, among other benefits.<\/p>\n

As of the Effective Time, every fifty shares of the Company\u2019s issued and outstanding common stock will be combined into one share of common stock. The par value per share of the Company\u2019s common stock will remain unchanged at $0.001. Proportional adjustments will be made to the number of shares of common stock issuable upon the exercise of the Company\u2019s equity awards, convertible securities and warrants, as well as the applicable exercise price, and the number of shares authorized and reserved for issuance pursuant to the Company\u2019s equity incentive plans.<\/p>\n

The Company\u2019s common stock will continue to trade on The Nasdaq Capital Market under the symbol \u201cWINT\u201d following the reverse stock split, with a new CUSIP number of 97382D 600. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced to approximately 700,000. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.<\/p>\n

The Company\u2019s transfer agent, Continental Stock Transfer and Trust Company, will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in \u201cstreet name\u201d will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker\u2019s particular processes, and will not be required to take any action in connection with the reverse stock split.<\/p>\n

Additional information about the reverse stock split can be found in the Current Report on Form 8-K filed today and in the Company\u2019s definitive proxy statement (Form DEF 14A) filed with the United States Securities and Exchange Commission on January 8, 2025.<\/p>\n

\n About Windtree Therapeutics, Inc.<\/strong>\n <\/p>\n

Windtree Therapeutics, Inc.\u00a0is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree\u2019s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitor that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place.<\/p>\n

\n Cautionary Statement Regarding Forward-Looking Statements<\/strong>\n <\/p>\n

Statements constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company\u2019s current expectations. Examples of such risks and uncertainties include, among other things: the Company\u2019s ability to acquire revenue generating subsidiaries; the market\u2019s reaction to potential acquisitions by the Company; the Company\u2019s ability to secure significant additional capital as and when needed; the Company\u2019s ability to achieve the intended benefits of the aPKCi asset acquisition with\u00a0Varian Biopharmaceuticals, Inc.; the Company\u2019s risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company\u2019s other product candidates, including preclinical oncology candidates; the Company\u2019s ability to access the debt or equity markets; the Company\u2019s ability to secure and successfully complete an out-licensing or asset acquisition transaction; the Company\u2019s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company\u2019s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the\u00a0U.S. Food and Drug Administration\u00a0or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company\u2019s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company\u2019s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company\u2019s product candidates, and the Company\u2019s ability to service those markets; the Company\u2019s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company\u2019s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between\u00a0Russia\u00a0and\u00a0Ukraine, the People\u2019s\u00a0Republic of China\u00a0and the\u00a0Republic of China\u00a0(Taiwan), and the evolving events in the\u00a0Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by\u00a0the United States\u00a0and\/or other countries which could have an adverse impact on the Company\u2019s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company\u2019s ability to access the capital markets. These and other risks are described in the Company\u2019s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the\u00a0Securities and Exchange Commission\u00a0and available at\u00a0www.sec.gov<\/a>. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n

Investors
Windtree:
Eric Curtis
ecurtis@windtreetx.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (\u201cWindtree\u201d or the \u201cCompany\u201d), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company\u2019s common stock. The Company\u2019s stockholders approved the reverse stock split proposal at the Company\u2019s Special Meeting of Stockholders held on February 3, 2025. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split. The reverse stock split will become effective on February 20, 2025 at 5:00 p.m., Eastern Time (the \u201cEffective Time\u201d), and the Company\u2019s common stock … <\/p>\n

Continue reading “Windtree Therapeutics, Inc. Announces Reverse Stock Split”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-814028","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nWindtree Therapeutics, Inc. Announces Reverse Stock Split - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Windtree Therapeutics, Inc. Announces Reverse Stock Split - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (\u201cWindtree\u201d or the \u201cCompany\u201d), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company\u2019s common stock. The Company\u2019s stockholders approved the reverse stock split proposal at the Company\u2019s Special Meeting of Stockholders held on February 3, 2025. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split. The reverse stock split will become effective on February 20, 2025 at 5:00 p.m., Eastern Time (the \u201cEffective Time\u201d), and the Company\u2019s common stock … Continue reading "Windtree Therapeutics, Inc. Announces Reverse Stock Split"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-18T13:09:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc2MSM2NzU0OTI2IzUwMDA3MzYyMA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Windtree Therapeutics, Inc. Announces Reverse Stock Split\",\"datePublished\":\"2025-02-18T13:09:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/\"},\"wordCount\":1291,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1OTc2MSM2NzU0OTI2IzUwMDA3MzYyMA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/\",\"name\":\"Windtree Therapeutics, Inc. Announces Reverse Stock Split - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1OTc2MSM2NzU0OTI2IzUwMDA3MzYyMA==\",\"datePublished\":\"2025-02-18T13:09:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1OTc2MSM2NzU0OTI2IzUwMDA3MzYyMA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1OTc2MSM2NzU0OTI2IzUwMDA3MzYyMA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-inc-announces-reverse-stock-split\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Windtree Therapeutics, Inc. Announces Reverse Stock Split\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Windtree Therapeutics, Inc. Announces Reverse Stock Split - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/","og_locale":"en_US","og_type":"article","og_title":"Windtree Therapeutics, Inc. Announces Reverse Stock Split - Market Newsdesk","og_description":"WARRINGTON, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (\u201cWindtree\u201d or the \u201cCompany\u201d), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company\u2019s common stock. The Company\u2019s stockholders approved the reverse stock split proposal at the Company\u2019s Special Meeting of Stockholders held on February 3, 2025. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split. The reverse stock split will become effective on February 20, 2025 at 5:00 p.m., Eastern Time (the \u201cEffective Time\u201d), and the Company\u2019s common stock … Continue reading \"Windtree Therapeutics, Inc. Announces Reverse Stock Split\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-18T13:09:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc2MSM2NzU0OTI2IzUwMDA3MzYyMA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Windtree Therapeutics, Inc. Announces Reverse Stock Split","datePublished":"2025-02-18T13:09:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/"},"wordCount":1291,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc2MSM2NzU0OTI2IzUwMDA3MzYyMA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/","name":"Windtree Therapeutics, Inc. Announces Reverse Stock Split - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc2MSM2NzU0OTI2IzUwMDA3MzYyMA==","datePublished":"2025-02-18T13:09:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc2MSM2NzU0OTI2IzUwMDA3MzYyMA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc2MSM2NzU0OTI2IzUwMDA3MzYyMA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-inc-announces-reverse-stock-split\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Windtree Therapeutics, Inc. Announces Reverse Stock Split"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=814028"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814028\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=814028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=814028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=814028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}